Drugs / HRS-7085
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06175949 | Dec 2023 → Jun 2024 | inflammatory bowel disease | Shandong Suncadia Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT05638347 | Dec 2022 → Mar 2023 | inflammatory bowel disease | Atridia Pty Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07229950 | Oct 2025 → Dec 2026 expected | — | Shandong Suncadia Medicine Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HRS-7085 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05638347 ↗ |
| Route | Oral | “Single oral administration” NCT05638347 ↗ |